中国肝脏病杂志(电子版)
中國肝髒病雜誌(電子版)
중국간장병잡지(전자판)
Chinese Journal of Liver Diseases (Electronic Version)
2015年
3期
92-95
,共4页
肝炎,乙型,慢性%肝纤维化%抗肝纤维化治疗%安络化纤丸
肝炎,乙型,慢性%肝纖維化%抗肝纖維化治療%安絡化纖汍
간염,을형,만성%간섬유화%항간섬유화치료%안락화섬환
Chronic hepatitis B%Liver fibrosis%Anti fibrosis treatment%Anluohuaxian capsule
目的:评价安络化纤丸治疗慢性乙型肝炎肝纤维化的有效性及安全性。方法采用随机开放性临床实验设计。选用慢性乙型肝炎肝纤维化患者72例,随机分配到实验组37例(安络化纤丸每次6克,口服,每天两次,疗程6个月),对照组35例(常规保肝组,疗程6个月)。治疗前后检测肝肾功能、肝纤维化指标(HA 、LN、PC-Ⅲ、Ⅳ-C)、血常规、B超。结果实验组血清肝纤维化指标改善优于对照组(P <0.05),实验组治疗后门脉主干内径及脾脏厚度较治疗前有明显缩小(P <0.05)。结论安络化纤丸具有明显的抗肝纤维化作用,是治疗慢性乙型肝炎肝纤维化的非常有效和安全的药物。
目的:評價安絡化纖汍治療慢性乙型肝炎肝纖維化的有效性及安全性。方法採用隨機開放性臨床實驗設計。選用慢性乙型肝炎肝纖維化患者72例,隨機分配到實驗組37例(安絡化纖汍每次6剋,口服,每天兩次,療程6箇月),對照組35例(常規保肝組,療程6箇月)。治療前後檢測肝腎功能、肝纖維化指標(HA 、LN、PC-Ⅲ、Ⅳ-C)、血常規、B超。結果實驗組血清肝纖維化指標改善優于對照組(P <0.05),實驗組治療後門脈主榦內徑及脾髒厚度較治療前有明顯縮小(P <0.05)。結論安絡化纖汍具有明顯的抗肝纖維化作用,是治療慢性乙型肝炎肝纖維化的非常有效和安全的藥物。
목적:평개안락화섬환치료만성을형간염간섬유화적유효성급안전성。방법채용수궤개방성림상실험설계。선용만성을형간염간섬유화환자72례,수궤분배도실험조37례(안락화섬환매차6극,구복,매천량차,료정6개월),대조조35례(상규보간조,료정6개월)。치료전후검측간신공능、간섬유화지표(HA 、LN、PC-Ⅲ、Ⅳ-C)、혈상규、B초。결과실험조혈청간섬유화지표개선우우대조조(P <0.05),실험조치료후문맥주간내경급비장후도교치료전유명현축소(P <0.05)。결론안락화섬환구유명현적항간섬유화작용,시치료만성을형간염간섬유화적비상유효화안전적약물。
Objective To evaluate the clinical efficacy and safety of Anluohuaxian capsule on treating patients with chronic hepatitis B and liver fibrosis. Methods A total of 72 patients with chronic hepatitis B and liver fibrosis were enrolled into this randomized and open clinical study. They were randomly divided into two groups: 37 cases in experimental group and 35 cases in control group. The experimental group were given Anluohuaxian capsule 6.0 g twice a day for six months and the control group were given conventional treatment. Liver and kidney function, blood routine, serum index of liver fibrosis and ultrasound were measured before and after treatment. Results Serum liver fibrosis indexes in experimental group were better than those of control group(P < 0.05). Portal vein diameter and thickness of the spleen in experimental group were significantly reduced after treatment(P < 0.05).Conclusions Anluohuaxian capsule is effective and well-tolerated for patients with chronic hepatitis B and liver fibrosis.